Sat.Mar 19, 2022 - Fri.Mar 25, 2022

article thumbnail

How to Stay Focused while Studying

Find Your Script

Studying is a skill…one that we may or may not have mastered during many years of education. I know I went through different study methods before settling on one that worked for me during 7 years of higher education. An important part of successful studying is staying focused. If you also want to improve study habits, see this post on the topic.

130
130
article thumbnail

Virtual and augmented reality: Bringing the future to pharma manufacturing

pharmaphorum

Virtual and augmented reality tools have reached a level of maturity to be utilised across various industries. In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR) and augmented reality (AR) have spent a lot of time in the headlines recently.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

Members of a multidisciplinary care team may include physicians, nurses, pharmacists, radiologists, dieticians…the list goes on. But one key member is often omitted: the patient’s caregiver. With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. Although the caregiver is seen as an extension of the patient and their role is not strictly defined, they are informal members of the front-line care team.

article thumbnail

AstraZeneca, Merck breast cancer treatment lands FDA approval

Outsourcing Pharma

The agency has approved Lynparza for use in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.

FDA 104
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

New 2022 Rates Position CMS’ Chronic Care Programs Are Ripe for Increased Revenue, Improved Outcomes

PharmD Live

If you’ve implemented chronic care management (CCM) or remote physiologic monitoring (RPM, a.k.a. remote patient monitoring) in your practice, you know that they generate new streams of revenue while allocating more time to take better care of your patients—with potentially life-saving results. In fact, Medicare is so confident that these programs will pay off that it has dramatically increased CCM overall reimbursement rates for 2022.

52
article thumbnail

Pharma’s ambition in connected health not yet matched by execution

pharmaphorum

Four out of five biopharma companies think that the market opportunity for connected health products exceeds their traditional drug business, but adoption remains low, with only 20% of use cases at present going beyond proof of concept. That’s one of the conclusions of a new study by Capgemini, which suggests that the number of approved connected health offerings – digital health products and services including wearables, digital therapeutics and software-as-a-medical-device (SaMD) – will

118
118

More Trending

article thumbnail

Janssen initiates psoriasis trial to bridge racial gaps in care

Outsourcing Pharma

The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.

article thumbnail

SmiLe Inject invests 2 MSEK in eHealth company developing a voice robot for the elderly

Pharma Mirror

SmiLe Incubator’s angel investment company, SmiLe Inject Capital, invests 2 MSEK in Call Knut, an incubator company that is developing a voice robot- based service using AI and ordinary phone calls as a complement in communicating with and caring for elderly people living on their own. The investment will be used to complete the development of the product and enable a commercial launch during the year.

article thumbnail

Google seeks FDA nod for passive AFib detection with Fitbit

pharmaphorum

Tech giant Google has filed for FDA approval to use its Fitbit wearable to help detect atrial fibrillation (AFib), a common heart abnormality that raises the risk of heart attack, stroke and sudden death. Fitbit is already approved by the FDA to provide electrocardiogram (ECG) monitoring of heart rhythms, and in 2020 its Sense Smartwatch was cleared by the regulator to use the ECG functionality to detect AFib – although that requires active input from the user.

FDA 117
article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

Over the years, the incidence and prevalence of chronic diseases, have increased significantly. Presently, the recommended treatment options for such clinical conditions are mostly biologics, which need to be administered via parenteral routes to ensure maximum therapeutic benefit. Given the inherent requirement for frequent medication, patients suffering from such long-lasting clinical conditions generally end up spending high amounts on the prescribed therapeutic regimen, and numerous hospital

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Pancreatic cancer organization adds new clinical trial sites

Outsourcing Pharma

The Pancreatic Cancer Action Network has engaged five new clinical trial sites in the US, which will aid in evaluation of Novartisâ investigational therapy.

97
article thumbnail

metaMe Health partners with Indegene to launch Regulora(R), an FDA-cleared Prescription Digital Therapeutic for adults with Irritable Bowel Syndrome

Pharma Mirror

PRINCETON, N.J. and CHICAGO. Indegene, a technology-led global healthcare solutions provider, and metaMe Health, Inc. (metaMe), a Prescription Digital Therapeutics (PDT) company and developer of Regulora®, today announced a partnership to bring Regulora to market for the treatment of abdominal pain due to Irritable Bowel Syndrome (IBS). IBS is a chronic condition that affects 10-15% of adults in the United States.

FDA 52
article thumbnail

The efficacy of Mental Health Apps

pharmaphorum

In January, PLOS Digital Health published a study which claimed that there’s “sparse” data to support the efficacy of most mental health apps. In their meta-analysis of published studies, the authors found universal deficiencies and concluded that there’s no convincing evidence that app-based interventions deliver meaningful outcomes. Without digging further, one might think the current case for digital therapeutics is weak.

FDA 113
article thumbnail

UK’s first digital health training programme for all NHS frontline staff

Pharma Times

The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff

66
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Ukraine war dramatically impacting global clinical development: Phesi

Outsourcing Pharma

The companyâs analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the countryâs borders.

59
article thumbnail

Polypharmacy and Pain Management – Podcast Special!

Med Ed 101

As a geriatric pharmacist, I understand how difficult it can be to manage polypharmacy and pain management. I had the honor of being invited onto the Pain Pod. This podcast is put together by Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS. We addressed many different aspects of polypharmacy and pain management in our 40+ minute […]. The post Polypharmacy and Pain Management – Podcast Special!

40
article thumbnail

AI tool helps detect leprosy using pictures

pharmaphorum

Ann Aerts, head of the Novartis Foundation, tells us about AI4Leprosy, a diagnostic assistant researchers developed that helps healthcare workers detect leprosy with over 90% accuracy using pictures of a patient’s skin lesion. . Leprosy has existed for more than 3,000 years and is the one of the oldest diseases known to humanity. Though a cure is available, 200,000 individuals are still diagnosed with the disease each year. “We’ve managed to reduce the burden of leprosy by 95%

109
109
article thumbnail

Highlights From Reuter’s Pharma USA 2022 | Philadelphia Convention Center

Pharma Marketing Network

Reuter’s Pharma USA 2022 was truly awesome. It feels great to finally get back “in person” and see people again. There was a strong showing of clients and a full agenda of great presentations. One of the overall themes that emerged based on the numerous case studies, examples, and presentations is that pharma has not been sitting still during COVID.

FDA 40
article thumbnail

Pfizer to supply up to 4m COVID-19 treatment courses to UNICEF

Outsourcing Pharma

The pharmaceutical company has agreed to provide its Paxlovid oral COVID-19 treatment to the global charity, covering 95 low- and middle-income countries.

article thumbnail

CDC Sees The Light! Pharmacist Reimbursement Is Necessary

Med Ed 101

Pharmacist reimbursement has been a frustrating battle for us pharmacists. We don’t get enough respect when it comes to legislation (i.e. provider status) and reimbursement of clinical services. There was a recent research article put out by the CDC that demonstrates the challenges that pharmacists face with regards to doing the right thing for patients […].

40
article thumbnail

Is your digital communication strategy up to par?

pharmaphorum

Whether you’re a large pharma company or a small, emerging one, communication is key. Success or failure hinges on communicating the advantages of your offerings to both prescribing providers and patients. Join us on Tuesday 12 th April at 13:00 BST / 14:00 CET / 8:00 am EDT as panelists lay out how a better approach to communication can lead to improved patient outcomes, preventing drop-off rates, better predicting product forecasts, increasing script volume, integrating localised digital strat

article thumbnail

NHS fast-tracks new targeted drug for rare lung cancer

Pharma Times

Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery

56
article thumbnail

Metabolomics: An Emerging yet Powerful Tool in Clinical Research and Development

Roots Analysis

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix- omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Likewise, metabolomics refers to the study of byproducts of metabolism.

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin.

article thumbnail

ViiV, J&J get FDA nod for simpler HIV injectable dosing

pharmaphorum

The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away with the need for an oral lead-in period. The label update means that people living with HIV who want to trade their daily oral doses of antiretroviral therapy (ART) for an injection delivered once a month or every two months will no long need to transition to oral therapy with the active ingredients in Cabenuva

FDA 98
article thumbnail

AstraZeneca’s Imfinzi fails in cervical cancer bid

pharmaphorum

AstraZeneca’s hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women with locally-advanced tumours. The CALLA trial compared Imfinzi (durvalumab) with chemoradiotherapy (CRT) to CRT alone in an all-comer cervical cancer population – regardless of PD-L1 biomarker status – hoping to extend the use of immunotherapy in this type of cancer.

article thumbnail

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

pharmaphorum

It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the deal. In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were intolerant to at least one prior conventional, biological or JAK inhibitor therapy.

98
article thumbnail

Handover of senior R&D roles at Merck continues, as Roy Baynes exits

pharmaphorum

Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roger Perlmutter at biotech Eikon Therapeutics. Baynes will bring a nine-year stint at Merck, known as MSD outside North America, to an end in July, when he will be replaced by Dr Eliav Barr, currently senior vice president of global clinical development.

article thumbnail

NHS grants fast-track access to Takeda’s lung cancer drug Exkivity

pharmaphorum

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Exkivity (mobocertinib) as a monotherapy for non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.

article thumbnail

IVRHA 2022: Exhibiting pioneers of medical XR

pharmaphorum

The International Virtual Reality Healthcare Association (IVRHA) held its 6th annual conference in Nashville, Tennessee, showcasing medical extended reality (XR) experiences and the companies impacting the healthcare ecosystem. As Adam Elsesser, CEO of Penumbra, stated in his keynote, when many people think of virtual reality, they often think of gaming.

article thumbnail

Ex-Biogen R&D head Sandrock takes the top job at Voyager

pharmaphorum

Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment coming just a few weeks after he joined the biotech’s board. Sandrock announced he was ending a 23-year career at Biogen last November, in the wake of the company’s controversial approval and disastrous rollout of Alzheimer’s therapy Aduhelm (aducanumab).

article thumbnail

Insulin price caps on the horizon as Senate leader plans vote

pharmaphorum

The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that was endorsed by President Joe Biden in his 2022 State of the Union address. Senate Majority Leader Chuck Schumer said yesterday that a vote on legislation which would introduce the cap – already backed in a House of Representatives vote last November – would take place this spring after the April recess.

article thumbnail

Government pledges to work with industry to make UK a genomics leader

pharmaphorum

With initiatives like The 100,000 Genome Project, the UK has led the world on genomic research. In a bid to maintain that position, the governments of all four UK nations have now pledged their support for the sectors’ industry players. Representatives from industry associations and the governments and NHS in all four UK nations will meet to discuss the future of the country’s genomics sector.

72
article thumbnail

Novartis gets first OK for radioligand Pluvicto in prostate cancer

pharmaphorum

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radioligand therapy for prostate cancer. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), a group with limited treatment options.